Provider Newsflash
May 2024

FDA Recall - Hospira, Inc.

Purpose of this communication:

- We are writing to inform you that effective immediately the FDA has issued notice of a voluntary recall initiated by Hospira, Inc., a Pfizer company ("Pfizer") of lot number HJ3965 and lot number HJ8546 of Buprenorphine Hydrochloride injection 0.3 mg base/mL single dose cartridge. Lot number HJ7566, lot number HN8747 and lot number HN8749 of Labetalol Hydrochloride injection 20 mg/4 mL (5 mg/mL) due to potential for incomplete crimp seals. The products were distributed nationwide to wholesalers/hospitals in the United States from September 2023 through April 2024. In the event, the impacted products are administered to a patient, there is a potential for an increased risk of lack of therapeutic effect and systemic infection that may result in the need for additional medical treatment.

What do I need to do?

- Please review the following recall notice: Hospira Inc. Issues A Voluntary Nationwide Recall For Buprenorphine Hydrochloride Injection CarpujectTM Units and Labetalol Hydrochloride Injection, USP CarpujectTM Units Due to the Potential for Incomplete Crimp Seals | FDA
- Notify impacted patients and facilitate the replacement and/or resolution of the recall, according to the guidelines issued by the manufacturer in the FDA notification.
- Confirm if you have any CareCentrix patients affected by this recall and notify the CareCentrix Quality Department by faxing information to: 919-792-6718 Attn: Quality Department.

Thank you in advance for your cooperation and continued partnership.